Big Pharma deal-making primed for acceleration
Subin Baral, Global Deals Leader, Life Sciences, Ernst & Young LLP, offers his predictions for M&A activity within industry as we head into the later stages of 2022.
List view / Grid view
Subin Baral, Global Deals Leader, Life Sciences, Ernst & Young LLP, offers his predictions for M&A activity within industry as we head into the later stages of 2022.
The $11.6 billion agreement will see Pfizer acquire Biohaven’s calcitonin gene-related peptide (CGRP) programmes, including migraine treatment rimegepant.
New research has found that of the drugs in the pre-registration phase, 10 are expected to become blockbusters over the next six years.